The ecosystem that powered the translation of OCT from fundamental research to clinical and commercial impact [Invited]

被引:112
作者
Swanson, Eric A. [1 ,2 ,3 ]
Fujimoto, James G. [1 ,2 ]
机构
[1] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA
[2] MIT, Elect Res Lab, Cambridge, MA 02139 USA
[3] Acacia Commun Inc, Maynard, MA 01754 USA
来源
BIOMEDICAL OPTICS EXPRESS | 2017年 / 8卷 / 03期
基金
美国国家卫生研究院;
关键词
OPTICAL COHERENCE TOMOGRAPHY; BREAST-CONSERVATION; BARRETTS-ESOPHAGUS; CANCER; STAGE; ENDOMICROSCOPY; ENDOSCOPY; CARCINOMA; SURGERY;
D O I
10.1364/BOE.8.001638
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
25 years is a relatively short period of time for a medical technology to become a standard of care impacting the treatment of millions of people every year. Yet 25 years ago there were no OCT companies, no OCT products, no OCT markets, and only one journal article published using the term OCT (optical coherence tomography). OCT has had a tremendous scientific, clinical, and economic impact on society. Today, it is estimated that there are similar to 30 Million OCT imaging procedures performed worldwide every year and the OCT system market is approaching $1B per year. OCT has helped diagnose patients with retinal disease at early treatable stages, preventing or greatly reducing irreversible vision loss. The technology has facilitated pharmaceutical development and contributed to fundamental understanding of disease mechanisms in multiple fields. The invention and translation of OCT from fundamental research to daily clinical practice would not have been possible without a complex ecosystem involving interaction among physics, engineering, and clinical medicine; government funding of fundamental and clinical research; collaborative and competitive research in the academic sector; entrepreneurship and industry; addressing real clinical needs; harnessing the innovation that occurs at the boundaries of disciplines; and economic and societal impact. This invited review paper discusses the translation of OCT from fundamental research to clinical practice and commercial impact, as well as describes the ecosystem that helped power OCT to where it is today and will continue to drive future advances. While OCT is an example of a technology that has had a powerful impact, there are many biomedical technologies which are poised for translation to clinical practice, and it is our hope that highlighting this ecosystem will help accelerate their translation and clinical impact. (C) 2017 Optical Society of America
引用
收藏
页码:1638 / 1664
页数:27
相关论文
共 50 条
[1]  
Ali Z. A, 2016, LANCLET
[2]  
Bezzera H., 2016, INTRAVASCULAR OCT 2
[3]  
Bezzera H., 2016, INTRAVASCULAR OCT 1
[4]  
Blumen H, 2016, AM HEALTH DRUG BENEF, V9, P23
[5]  
Boppart S. A., 1998, US Patent, Patent No. [6485413B1, 6485413]
[6]   Systematic review of optical coherence tomography usage in the diagnosis and management of basal cell carcinoma [J].
Cheng, H. M. ;
Guitera, P. .
BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (06) :1371-1380
[7]   Biophotonic endoscopy: a review of clinical research techniques for optical imaging and sensing of early gastrointestinal cancer [J].
Coda, Sergio ;
Siersema, Peter D. ;
Stamp, Gordon W. H. ;
Thillainayagam, Andrew V. .
ENDOSCOPY INTERNATIONAL OPEN, 2015, 3 (05) :E380-E392
[8]   A pathologic assessment of adequate margin status in breast-conserving therapy [J].
Dillon, MF ;
Hill, ADK ;
Quinn, CM ;
McDermott, EW ;
O'Higgins, N .
ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (03) :333-339
[9]  
Drexler W., 2015, Optical Coherence Tomography: Technology and Applications, V2
[10]  
Fujimoto J. G., 2016, INVES OPHTHALMOL VIS